Forward WE Go supports Medical Affairs in the strategic development of Scientific Platforms to plan and execute medical communications in a consistent, evidence-based manner

Phase 2 or Earlier

Is it too early to develop a Scientific Platform? We don’t have our Phase 3 study results yet… 

• It’s actually ideal to get a head start, at minimum to lay out the disease state education and current treatment landscape.
• This initial assessment may reveal gaps that could inform future research, in hopes of showing how your product could address an unmet need.
• If you are starting to mobilize your Medical Science Liaisons at this stage, it will be important to make sure that their communications are consistent with the Scientific Platform.

Phase 3 or Pre-Launch

There’s so much in flux at this time, with new data presented at various scientific congresses. Shouldn’t we wait until things settle a bit before establishing a Scientific Platform, especially since the cross-functional teams are all in motion?

• As results from the pivotal trials become available, the bulk of the product-related portions of the Scientific Platform can be developed to assure a consistent, evidence-based interpretation of the data.
• Medical Affairs is often at the forefront of the Scientific Platform, rather than following in the path of the cross-functional teams.

Post-Launch

We already have a Scientific Platform. We don’t see a reason to change it.

• Scientific Platforms should be a living document, evolving over time as new data milestones are met, major changes are made to the program, or the treatment landscape changes with the introduction of new competitors

Contact:

LoAn K. Ho, PharmD
LoAn@WesleyEnterprise.net